NasdaqGM - Nasdaq Real Time Price ? USD Gain Therapeutics, Inc. (GANX) Follow Compare 2.2300 -0.0400 (-1.76%) At close: November 7 at 4:00 PM EST 2.2700 +0.04 (+1.79%) After hours: November 7 at 4:20 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Gain Therapeutics Presents Data at 36?? EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 GT-03842, Identified by the Company’s Magellan Drug Discovery Platform, Effectively Hinders Phosphorylation and Activation of DDR2 GT-03842 May Offer Potential Favourable Therapeutic Attributes for Oncology Compared to Traditional Kinase Inhibitors BETHESDA, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therap GlobeNewswire ? 15 days ago GANX -1.76% Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the use of the Company’s Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors will be presented at the 36th EORTC-NCI-AACR (ENA) Symposium on molecular targets and GlobeNewswire ? 23 days ago GANX -1.76% Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of Gain, will give an oral presentation on the Company’s clinical stage lead drug candidate GT-02287 at the Michael J. Fox Foundation’s (MJFF) 16th Annual Parkinson’s Dise GlobeNewswire ? 29 days ago GANX -1.76% Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson’s Disease Models GT-02287 Prevents Tau Accumulation in a Cellular Model BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric GlobeNewswire ? last month GANX -1.76% Gain Therapeutics to Participate at Upcoming Investor Conferences BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, interim Chief Executive Officer and current Chief Financial Officer of Gain, will participate in two upcoming investor conferences: 3rd Annual ROTH Healthcare Opportunities Conference on Wednesday, October 9. Gen GlobeNewswire ? last month GANX -1.76% Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers GT-02287 Increases Peripheral GCase Activity GT-02287 Demonstrates CNS Exposure Company to Host Webinar to Discuss Results at 8:30 AM ET Today BETHESDA, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of a late-breaking abstract at the International Congress of Parkin GlobeNewswire ? last month GANX -1.76% Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson’s Disease Patients Event Will Be Held on Monday, September 30, 2024, at 8:30 am ET BETHESDA, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a we GlobeNewswire ? last month GANX -1.76% Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024 BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced presentations, including two late-breakers, at Neuroscience 2024 featuring preclinical data supporting development of GT-02287, the Company’s clinical stage lead drug candidate, in Parkinson’s disease with or without a GBA1 mut GlobeNewswire ? last month GANX -1.76% Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Interim CEO and current CFO of Gain, and Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of Gain, will participate in a corporate presentation and one-on-one meetings at the H.C. Wainwright 26th Annual Globa GlobeNewswire ? 2 months ago GANX -1.76% Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial In the trial, GT-02287 was found to be safe and well-tolerated at all dose levels, including the highest planned doses. Clinical Trials Arena ? 2 months ago GANX -1.76% Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson’s Disease, on Track to Initiate Phase 1b Trial in Patients in Q4 2024 BETHESDA, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces positive results from the Phase 1 study co GlobeNewswire ? 2 months ago GANX -1.76% Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 Initiation of Phase 1b Study of GT-02287 in Parkinson’s Disease Patients Anticipated in Q4 2024 BETHESDA, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, GlobeNewswire ? 2 months ago GANX -1.76% Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference BETHESDA, Md. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s interim-CEO and current CFO, Gene Mack, and Chief Medical Officer, Jonas Hannestad, will participate in a fireside chat and one-on-one meetings at BTIG’s Virtual Biotechnology Conference taking place August 5 GlobeNewswire ? 3 months ago GANX -1.76% 7 Sorry Biotech Stocks Set to Make Investors Sad Biotech stocks are not for everyone, let’s make that perfectly clear. It’s challenging to invest in a field in which companies – particularly startups – can go for years without seeing a penny of revenue. While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get into too much trouble. Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and te InvestorPlace ? 3 months ago TNXP OVID GANX -1.76% Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson’s Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the las GlobeNewswire ? 3 months ago GANX -1.76% Gain Therapeutics (GANX) Upgraded to Buy: Here's Why Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Zacks ? 3 months ago GANX -1.76% Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024 BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open. Participants can join the conference call through the News and Events sectio GlobeNewswire ? 4 months ago GANX -1.76% Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO Mr. Mack is the Company’s Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder’s dep GlobeNewswire ? 4 months ago GANX -1.76% Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficitsBETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the presentation of a poster at the Federation of European Neuroscience Societies (FENS) For GlobeNewswire ? 4 months ago GANX -1.76% Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference taking place June 27, 2024. Pr GlobeNewswire ? 4 months ago GANX -1.76% Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return GANX S&P 500 YTD -31.70% +25.23% 1-Year -19.49% +36.81% 3-Year -71.37% +27.15%
